Brokerages Set Ralliant Corporation (NYSE:RAL) PT at $69.00

Shares of Ralliant Corporation (NYSE:RAL) have been assigned an average recommendation of “Moderate Buy” from the twelve ratings firms that are presently covering the firm, MarketBeat.com reports. One equities research analyst has rated the stock with a sell recommendation, three have given a hold recommendation, seven have issued a buy recommendation and one has assigned a strong buy recommendation to the company. The average 1 year price objective among brokerages that have covered the stock in the last year is $69.00.

A number of analysts have issued reports on the company. Weiss Ratings reaffirmed a “sell (d)” rating on shares of Ralliant in a report on Monday, May 4th. Vertical Research cut Ralliant from a “buy” rating to a “hold” rating and set a $65.00 price objective for the company. in a research report on Wednesday, May 27th. Barclays raised their price objective on shares of Ralliant from $52.00 to $67.00 and gave the stock an “overweight” rating in a research note on Wednesday, May 13th. Zacks Research raised shares of Ralliant from a “hold” rating to a “strong-buy” rating in a research report on Tuesday, June 30th. Finally, Truist Financial reiterated a “buy” rating and set a $68.00 target price (up from $53.00) on shares of Ralliant in a research note on Wednesday, May 13th.

Ralliant Stock Performance

RAL stock traded down $1.49 during mid-day trading on Tuesday, reaching $67.77. 509,771 shares of the stock traded hands, compared to its average volume of 1,697,109. The firm has a market capitalization of $7.59 billion and a PE ratio of -6.20. The business has a 50-day moving average of $61.08 and a two-hundred day moving average of $52.07. Ralliant has a 52 week low of $37.27 and a 52 week high of $75.41. The company has a quick ratio of 1.05, a current ratio of 1.61 and a debt-to-equity ratio of 0.73.

Ralliant (NYSE:RAL) last posted its quarterly earnings data on Tuesday, May 12th. The company reported $0.57 EPS for the quarter, topping analysts’ consensus estimates of $0.49 by $0.08. Ralliant had a positive return on equity of 12.49% and a negative net margin of 58.55%.The business had revenue of $534.60 million for the quarter. The company’s revenue was up 11.0% compared to the same quarter last year. Ralliant has set its FY 2026 guidance at 2.530-2.690 EPS and its Q2 2026 guidance at 0.580-0.640 EPS. As a group, equities analysts predict that Ralliant will post 2.64 EPS for the current fiscal year.

Ralliant Announces Dividend

The business also recently disclosed a quarterly dividend, which was paid on Tuesday, June 23rd. Stockholders of record on Monday, June 8th were issued a dividend of $0.05 per share. The ex-dividend date was Monday, June 8th. This represents a $0.20 annualized dividend and a dividend yield of 0.3%. Ralliant’s payout ratio is presently -1.83%.

Institutional Investors Weigh In On Ralliant

Hedge funds have recently made changes to their positions in the stock. Cetera Investment Advisers bought a new position in Ralliant during the second quarter valued at about $700,000. Russell Investments Group Ltd. bought a new stake in shares of Ralliant in the 2nd quarter worth approximately $1,465,000. EverSource Wealth Advisors LLC bought a new stake in shares of Ralliant in the 2nd quarter worth approximately $39,000. First Trust Advisors LP acquired a new stake in shares of Ralliant during the 2nd quarter worth approximately $2,013,000. Finally, Federated Hermes Inc. bought a new stake in shares of Ralliant during the second quarter valued at approximately $326,000.

Ralliant Company Profile

Ralliant, Inc (NYSE: RAL) is a medical technology company focused on enabling point-of-care cell therapy solutions in the field of regenerative medicine. The company develops and markets systems that isolate, concentrate and store adipose-derived stromal vascular fraction (SVF) cells directly from a patient’s own fat tissue, facilitating same-day, autologous treatments without the need for extensive laboratory infrastructure.

The company’s core product portfolio includes proprietary device platforms and single-use processing kits engineered to streamline the workflow for clinicians.